Pancreatitis
Recent clinical, regulatory, research and industry developments relating to this disease.
Incretin mimetics and acute pancreatitis: enemy or innocent bystander?
Immune markers of severe acute pancreatitis.
Toll-like receptor 4 in pancreatic damage and immune infiltration in acute pancreatitis.
Gut microbiota predicts severity and reveals novel metabolic signatures in acute pancreatitis.
Acute Pancreatitis: Diagnosis and Treatment.
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
- 3 clinical trials expected to report results, the earliest in Q4 2026.
- Active recent publication activity.
- 1 industry development reported.
- Q4 2026A Randomized Trial Comparing Rectal Indomethacin Alone Versus a Combination of Rectal Indomethacin and Oral Tacrolimus for Post-ERCP Pancreatitis Prophylaxis
- Q3 2027Precise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis: A Randomized Controlled Trial
- Q2 2028Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic Pancreatitis
Research HighlightsViewHide
- 2025-09-01Evaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Wen J · 2025
- 2026-02-16The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.Jalleh RJ · 2026
Clinical MilestonesViewHide
- 2026-06-09Anti-inflammatory Therapy to Improve Outcomes in Patients With Chronic Pancreatitis Undergoing Total Pancreatectomy Islet AutotransplantationResults posted
- 2026-03-12Post ERCP Pancreatitis Prophylaxis, Effectiveness of Rectal Indomethacin vs Intravenous Ketorolac in the Pediatric PopulationResults posted
- 2026-04-27Malabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic PancreatitisResults expected Q2 2028
- 2025-12-09A Randomized Trial Comparing Rectal Indomethacin Alone Versus a Combination of Rectal Indomethacin and Oral Tacrolimus for Post-ERCP Pancreatitis ProphylaxisResults expected Q4 2026
- 2025-12-08Precise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis: A Randomized Controlled TrialResults expected Q3 2027
Industry & MarketViewHide
- 2026-07-15Chronic Pancreatitis Therapies Informed by Patient-Derived OrganoidsIndustry · GEN News
- 2026-07-15IndustryChronic Pancreatitis Therapies Informed by Patient-Derived OrganoidsIndustry · GEN News
- 2026-07-01ClinicalA Randomized Controlled Trial of IV Ketorolac to Prevent Post-ERCP PancreatitisWithdrawn
- 2026-06-09ClinicalAnti-inflammatory Therapy to Improve Outcomes in Patients With Chronic Pancreatitis Undergoing Total Pancreatectomy Islet AutotransplantationResults posted
- 2026-04-27ClinicalMalabsorption Blood Test (MBT) to Determine Exocrine Pancreatic Function and Related Quality of Life in Chronic PancreatitisResults expected Q2 2028
- 2026-03-12ClinicalPost ERCP Pancreatitis Prophylaxis, Effectiveness of Rectal Indomethacin vs Intravenous Ketorolac in the Pediatric PopulationResults posted
- 2026-02-16ResearchThe science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.Jalleh RJ · 2026
- 2025-12-09ClinicalA Randomized Trial Comparing Rectal Indomethacin Alone Versus a Combination of Rectal Indomethacin and Oral Tacrolimus for Post-ERCP Pancreatitis ProphylaxisResults expected Q4 2026
- 2025-12-08ClinicalPrecise Endoscopic Application of Nitroglycerin in Preventing Post-ERCP Pancreatitis: A Randomized Controlled TrialResults expected Q3 2027
- 2025-09-01ResearchEvaluating the Rates of Pancreatitis and Pancreatic Cancer Among GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.Wen J · 2025
Therapeutic landscape
Therapies with a regulatory footing for this condition, alongside the wider set of agents co-studied with it in the literature.
Approval — Waylivra is indicated as an adjunct to diet in adult patients with genetically confirmed… (2019)
Clinical trials
The current development programme across all trial phases.
Regulatory timeline
Drug regulatory events matched to this condition by indication — EMA.
European Medicines Agency (CC BY 4.0). Events are matched to this condition by drug indication text — approvals/updates for drugs indicated for it, not disease-specific acts.
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Major themes8
- Pancreatitis8
- Diabetes Mellitus, Type 25
- Glucagon-Like Peptide-1 Receptor Agonists4
- Hypoglycemic Agents3
- Incretins2
- Antibiotic Prophylaxis1
- Biomarkers1
- Cholangiopancreatography, Endoscopic Retrograde1
Leading journals6
- Current opinion in gastroenterology2
- Gut2
- Diabetes research and clinical practice1
- Drugs1
- Endocrinology, diabetes & metabolism1
- Frontiers in endocrinology1
Leading researchers8
- Beyer G2
- Acosta RD1
- Agrawal D1
- Alam A1
- Ammer-Herrmenau C1
- Antweiler KL1
- Asendorf T1
- Beckingham I1
Affiliations (unnormalised)6
- Adelaide Medical School1
- AdventHealth Translational Research Institute1
- Aintree University Hospital Liverpool1
- and Nutrition. Ohio State University Wexner Medical Center1
- Baylor University1
- Baylor University Medical Center1
Disease biology
Key proteins & gene products studied in this disease. Number shows shared papers.
Related conditions
Diseases frequently studied alongside this one. Number shows shared papers.
Disease profile
A grounded synthesis of the condition — overview, causes, mechanism, risk factors and current standard of care.
Pancreatitis is inflammation of the pancreas. It is classified as acute unless imaging shows chronic pancreatitis, and the common acute forms are alcoholic pancreatitis and gallstone pancreatitis. Acute pancreatitis is a common reason for hospital admission and can range from mild disease to severe illness with persistent organ failure.
The main causes described are gallstones and ethanol. Other noted causes include hypertriglyceridaemia, drugs, genetics, and ductal obstruction caused by calcification or neutrophil extracellular traps. Common bile duct stones can also lead to acute pancreatitis.
Acute pancreatitis is an inflammatory disorder of the pancreas associated with pancreatic injury and immune activation. The literature describes immune cell infiltration, especially neutrophils and M1 macrophages, and a disordered immune response that can drive systemic inflammatory response syndrome and systemic injury in severe disease. TLR4-mediated inflammatory signaling and NLRP3-inflammasome-related pathways are implicated in pancreatic damage and severe acute pancreatitis.
Gallstones and alcohol use are the most prominent risk factors in the supplied material. Hypertriglyceridaemia, drugs, and ductal obstruction are also noted, and common bile duct stones can predispose to acute pancreatitis. The literature also mentions genetics as a contributing factor.
Management is described at the modality level as hospital-based supportive care with diagnostic evaluation and imaging to assess severity and complications. For pancreatitis related to common bile duct stones, endoscopic retrograde cholangiopancreatography, surgery, and radiological stone extraction are used. The literature also notes that treatment decisions depend on identifying complications and the underlying cause.
AI-generated summary grounded in MeSH and 6 peer-reviewed sources. Informational only — not medical advice. Generated 2026-07-07.
Reference
Authoritative identity, definition & identifiers.
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.